3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Multiple Myeloma
114
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Recurrence
17
Burkitt Lymphoma
14
Lymphoma, Large B-Cell, Diffuse
8
Neoplasms
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
6
Neoplasms, Plasma Cell
6
Lymphoma
6
Leukemia, Biphenotypic, Acute
5
Immunoglobulin Light-chain Amyloidosis
5
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
4
Lymphoma, Non-Hodgkin
4
Lymphoma, B-Cell
4
Waldenstrom Macroglobulinemia
3
Neoplasm Metastasis
3
Nausea
3
Lung Neoplasms
3
Leukemia
3
Smoldering Multiple Myeloma
2
Rectal Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Paraproteinemias
2
Ovarian Neoplasms
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Down Syndrome
2
Interventions
Fluorouracil
13
pembrolizumab
12
Paclitaxel
12
Oxaliplatin
12
Leucovorin
9
Carboplatin
9
Capecitabine
8
Trastuzumab
7
Nivolumab
7
Cisplatin
7
Radiotherapy
6
Radiation
6
Taxes
5
Esophagectomy
5
Drug Therapy
5
Surgical Procedures, Operative
4
Specimen Handling
4
Irinotecan
4
trastuzumab deruxtecan
3
tislelizumab
3
patritumab deruxtecan
3
Radiotherapy, Intensity-Modulated
3
Proton Therapy
3
Immunotherapy
3
zanidatamab
2
ulixertinib
2
trastuzumab biosimilar HLX02
2
relatlimab
2
durvalumab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Dexamethasone
×
90 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled